Engage Bio develops Tethosomes, a non-viral DNA platform for effective, durable, and scalable genetic medicine, addressing challenges in gene therapy.
Founded
2021
Company Stage
Seed
YC Batch
W22
Product Features & Capabilities
Tethosomes, non-viral DNA delivery platform, highly potent (over 100x expression), non-immunogenic, redosable (months to years of expression), ready to scale (low manufacturing complexity).
How much Engage Bio raised
Seed - $125K
March 29, 2022
Lead Investor: Y Combinator, WorldQuant Ventures, and 2 others.
